Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable fixed combination of doravirine, a pyridinone non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1), lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) analog of cytidine, and the fumarate salt form of the prodrug tenofovir disoproxil, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of doravirine/lamivudine/tenofovir disoproxil, doravirine non-competitively inhibits HIV-1 reverse transcriptase (RT), thereby inhibiting HIV-1 viral replication. Lamivudine is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP), that competes for incorporation into viral DNA, and tenofovir disoproxil, upon conversion into tenofovir, also competes with natural deoxyribonucleosides for incorporation into the growing viral DNA chain, thereby inhibiting the HIV RT competitively and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.

**Synonyms:** - Delstrigo - Delstrigo